Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis

Oryoji, Kensuke; Yoshida, Kenji; Kashiwado, Yusuke; Tanaka, Keiko; Mizuki, Shin Ichi; Tsukamoto, Hiroshi; Kamada, Kohei; Akashi, Koichi

doi:10.1136/annrheumdis-2017-211430

Cited by 22 publications

(24 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Briefly, after 24 weeks of abatacept exposure in SE-positive patients, the proportion of subjects who achieved ACR 20, 50 and 70 responses were significantly higher compared to the adalimumab group [153]. These results are in line with the particular effectiveness of abatacept in the SE-positive group demonstrated in a previous Japanese study ( Figure 6) [154]. [154] csDMARDs = classical synthetic disease-modifying antirheumatic drugs; CsA = cyclosporine; ADA = adalimumab; ABA = abatacept.…”

Section: Abataceptsupporting

confidence: 79%

Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis–From Research to Clinical Practice

Wysocki

Olesińska

Paradowska‐Gorycka

2020

Cells

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease with an unclear pathogenic mechanism. However, it has been proven that the key underlying risk factor is a genetic predisposition. Association studies of the HLA-DRB1 gene clearly indicate its importance in RA morbidity. This review presents the current state of knowledge on the impact of HLA-DRB1 gene, functioning both as a component of the patient’s genome and as an environmental risk factor. The impact of known HLA-DRB1 risk variants on the specific structure of the polymorphic HLA-DR molecule, and epitope binding affinity, is presented. The issues of the potential influence of HLA-DRB1 on the occurrence of non-articular disease manifestations and response to treatment are also discussed. A deeper understanding of the role of the HLA-DRB1 gene is essential to explore the complex nature of RA, which is a result of multiple contributing factors, including genetic, epigenetic and environmental factors. It also creates new opportunities to develop modern and personalized forms of therapy.

show abstract

Section: Abataceptsupporting

confidence: 79%

Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis–From Research to Clinical Practice

Wysocki

Olesińska

Paradowska‐Gorycka

2020

Cells

View full text Add to dashboard Cite

show abstract

“…It was recently reported that changes in RAautoantibody levels were not associated with disease activity but reflected intensity of immunosuppression, although abatacept was not included in the analysis [15]. In addition, the presence of shared epitope rather than ACPA predicts clinical response to abatacept in RA [16], suggesting that ACPA might be an indicator of T cell-involvement in the pathogenesis. There are also lines of evidence implicating T-cell-independent effect of abatacept on monocytes/macrophages and osteoclasts [17,18].…”

Section: Discussionmentioning

confidence: 99%

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production

Yamada

Tsuru

Otsuka³

et al. 2020

Immunological Medicine

Self Cite

View full text Add to dashboard Cite

Abatacept may exert its clinical effect on rheumatoid arthritis (RA) by suppressing anti-cyclic citrullinated peptide (CCP) antibody production. This study was undertaken to test this hypothesis by examining the changes of disease activity of RA and anti-CCP antibody levels over time after starting abatacept. Sixty Japanese RA patients who started abatacept were included in this multicenter, prospective observational study. Simple Disease Activity Index (SDAI) and anti-CCP antibody levels were evaluated at 12, 24, and 52 weeks. The mean SDAI score significantly decreased within 12 weeks after starting abatacept and was maintained thereafter. On the contrary, the mean anti-CCP antibody levels did not change until 52 weeks. At the individual level, there were substantial changes of anti-CCP antibody levels, but these were not correlated with the changes of disease activity at any time points. Thus, abatacept reduces the disease activity of RA independently of modulating anti-CCP antibody production.

show abstract

“…To our knowledge, this is the first economic analysis for RA patients with SE+ as well as ACPA+ and RF+. This is important because recent studies have found that SE+ is an independent predictor of SDAI remission apart from ACPA titer, 16 so economic analyses for this biomarker can help in decision-making. Previous economic assessment studies using data from the phase 3 AMPLE trial (NCT00929864) looked into RA biomarkers including RF and ACPA but did not include SE.…”

Section: Discussionmentioning

confidence: 99%

“…15 Additionally, Oryoji et al retrospectively evaluated 72 Japanese patients (45 SE+ and 25 SE-) treated with abatacept and found that the Simple Disease Activity Index (SDAI) remission was higher among SE+ patients at week 24 (55.3% vs 20.0%, p=0.01) and the SE status was an independent predictor of SDAI remission after adjusting for ACPA titer, age, sex, SDAI at baseline, methotrexate use, and prior use of biological agents. 16 Despite the illustrated efficacy of abatacept among seropositive patients, economic assessments of abatacept compared with adalimumab and other TNFis are currently unavailable. To address this gap for economic evaluation, we developed a cost per responder (CPR) model to compare CPR between abatacept SC and adalimumab SC from a US payer perspective among early moderate-to-severe RA patients with seropositivity (SE+, ACPA+, and RF+) using the results from the post hoc analysis of the Early AMPLE trial.…”

Section: Introductionmentioning

confidence: 99%

<p>A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity</p>

Park

Han

Lobo

et al. 2020

CEOR

View full text Add to dashboard Cite

Purpose: The primary objective of this study was to compare the cost per responder (CPR) between abatacept and adalimumab among seropositive rheumatoid arthritis (RA) patients. Patients and Methods: CPR analysis was conducted from a US payer perspective over 24 weeks for early moderate-to-severe seropositive RA patients. Efficacy data (American College of Rheumatology [ACR] improvement criteria [ACR20/50/70] and DAS28-C reactive protein <2.6) for abatacept and adalimumab were sourced from the post hoc analysis of the Early AMPLE trial (NCT02557100).

show abstract

Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis

Cited by 22 publications

References 10 publications

Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis–From Research to Clinical Practice

Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis–From Research to Clinical Practice

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production

<p>A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity</p>

Contact Info

Product

Resources

About